Showcasing teva's commitment to helping patients have more migraine-free days, 18 abstracts will be presented, including one late-breaker, on ajovy® (fremanezumab-vfrm) injection at the international headache society and european headache.

Tel aviv, israel & parsippany, n.j.--(business wire)--showcasing teva's commitment to helping patients have more migraine-free days, 18 abstracts will be presented, including one late-breaker, on ajovy® (fremanezumab-vfrm) injection at the international headache society and european headache federation joint congress 2021 teva pharmaceuticals usa, inc., a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced that 17 presentations, including one late-breake
TEVA Ratings Summary
TEVA Quant Ranking